Crowley John F's Form 4/A amendment
AmendedAmicus Therapeutics, Inc.FOLD · filed Mar 15, 2024
- Accession no.
- 0000950170-24-032406
- Filed
- Mar 15, 2024
- Trade date
- Jan 9-10, 2024
- Filing delay
- 66 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Jan 11, 2024
This filing lists 3 non-derivative transactions. Open-market sales total $431.5K. It was filed 66 days after the trade.
This amendment replaces 0000950170-24-004042 (filed Jan 11, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crowley John FCIK 0001400973 | Director, Officer (Executive Chairman) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 9, 2024 | Common Stock | AGrant or awardAcquired | +57,620 | $0.00F1 | $0 | 995,492 | Direct | |
| Jan 9, 2024 | Common Stock | FTax withholdingDisposed | −36,865 | $13.65 | −$503,207.25 | 958,627 | Direct | |
| Jan 10, 2024 | Common Stock | SSaleDisposed | −31,614 | $13.65F3 | −$431,531.1 | 927,013 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
Referenced by the price of 1 transaction in Table I.
- F2
On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
- F3
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
The sale transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2023.